Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/03/2002WO2002062293A3 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/03/2002WO2002055533A3 Methods of using imxp-888 and imxp-888 antagonists
10/03/2002WO2002040070A3 Method for restoring a damaged or degenerated intervertebral disc
10/03/2002WO2002029086A3 Nucleic acid sequences differentially expressed in cancer tissue
10/03/2002WO2002026193A3 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
10/03/2002WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002WO2002004949A3 Reagents and methods for identification of binding agents
10/03/2002WO2002002751A3 Alteration of cell membrane
10/03/2002WO2001094627A3 Assay techniques based on growth stage dependent expression in c. elegans
10/03/2002WO2001085095A3 Chiral fluoroquinolizinone arginine salt forms
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2000069896A9 Molecular interactions in haematopoietic cells
10/03/2002US20020143176 For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH)
10/03/2002US20020143162 Methods
10/03/2002US20020143039 Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
10/03/2002US20020143033 Administering therapeutically-effective amount of a 5-lipoxygenase inhibitor and a cyclooxygenase-2 inhibitor selected from Dupont Dup 697, Taisho NS-398, meloxicam, flosulide and heterocyclic compounds
10/03/2002US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002US20020143028 For therapy of pain
10/03/2002US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002US20020143015 Use of vardenafil or pharmaceutically or veterinarily acceptable salt, or solvate in preparation of a medicament for curative, palliative or prophylactic therapy of type 2 diabetes mellitus
10/03/2002US20020143010 Compounds for treating fibromyalgia and chronic fatigue syndrome
10/03/2002US20020143007 Donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase; for use in therapy
10/03/2002US20020142990 Locally administering to a human an axon of neuron therapeutically effective amount of activator of cyclic nucleotide dependent protein kinase, whereby growth of axon is promoted; detecting a resultant growth promotion of axon
10/03/2002US20020142988 G-coupled receptor showing selective affinity for ATP
10/03/2002US20020142985 Therapeutic compositions and methods of treating glycolipid storage related disorders
10/03/2002US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002US20020142982 Method for regulating angiogenesis
10/03/2002US20020142956 Administering an agent which triggers anion efflux in respiratory tissue via the activation of a secretin receptor for therapy of cystic fibrosis
10/03/2002US20020142950 Methods for enhancing the bioavailability of a drug
10/03/2002US20020142943 A drug and an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine residue of p100 and/or p120, wherein the ability of the drug to cross a physiological barrier is improved.
10/03/2002US20020142941 Intraductal treatment targeting methylated promoters in breast cancer
10/03/2002US20020142940 Method of inhibiting viral infection using HMG-COA reductase inhibitors and isoprenylation inhibitors
10/03/2002US20020142447 DNA encoding the human serine protease EOS
10/03/2002US20020142446 DNA encoding the human serine protease EOS
10/03/2002US20020142436 Enzymatic protein for use in the treatment of tumors, nervous system, cardiovascular, psychological, pregnancy, bone, kidney, respiratory and alimentary canal disorders
10/03/2002US20020142430 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
10/03/2002US20020142392 Human melanocyte stimulating hormone receptor polypeptide and DNA
10/03/2002US20020142378 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/03/2002US20020142348 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
10/03/2002US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
10/03/2002US20020142296 Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins
10/03/2002US20020142283 Inhibitors of C-reactive protein induced inflammation
10/03/2002US20020142049 Precipitating drug as solid
10/03/2002US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002US20020142035 Metering and packaging of controlled release medication
10/03/2002US20020142029 Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments
10/03/2002US20020142012 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations
10/03/2002US20020142010 Administering neurotoxin
10/03/2002US20020141993 Apoptosis; anticancer agents
10/03/2002US20020141992 Deactivation of collagen receptors
10/03/2002US20020141991 Methods of treating inflammatory disease using antibodies which bind GPR-9-6
10/03/2002US20020141985 Dietetics, eating disorders, antidiabetic agents
10/03/2002CA2692295A1 Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer
10/03/2002CA2664797A1 Cytotoxic factors for modulating cell death
10/03/2002CA2448179A1 Methods for forming hardened tubes and sheets
10/03/2002CA2442089A1 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
10/03/2002CA2442080A1 A preparation for restenosis prevention
10/03/2002CA2442012A1 Chemical derivatives and their use as anti-telomerase agent
10/03/2002CA2442004A1 Microbial feeds for aquaculture and agriculture
10/03/2002CA2442003A1 Methods for treating neurodegenerative diseases including alzheimer's
10/03/2002CA2441926A1 (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides
10/03/2002CA2441889A1 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
10/03/2002CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002CA2441721A1 Human potassium channel
10/03/2002CA2441706A1 A new essential downstream component of the wingless signalling pathway
10/03/2002CA2441700A1 Polypeptides and nucleic acids for bolekine
10/03/2002CA2441599A1 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
10/03/2002CA2441588A1 Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders
10/03/2002CA2441577A1 Therapeutic agents for inflammatory bowel diseases
10/03/2002CA2441568A1 Pharmaceutical combinations for the treatment of cancer
10/03/2002CA2441394A1 Agents and methods for treatment of cancer
10/03/2002CA2441378A1 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
10/03/2002CA2441377A1 Protein phosphate inhibitors
10/03/2002CA2441228A1 Combination treatment of pancreatic cancer
10/03/2002CA2441092A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002CA2439630A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/03/2002CA2439409A1 Inhibitors of glycosaminoglycans
10/03/2002CA2438206A1 Transporters and ion channels
10/03/2002CA2436340A1 Histidine-rich glycoprotein
10/03/2002CA2434691A1 Use of propentofylline to control intraocular pressure
10/03/2002CA2410469A1 Improved forms of pharmaceutically active agents and method for manufacture thereof
10/02/2002EP1244916A1 INHIBITION OF $g(b)ARRESTIN MEDIATED EFFECTS PROLONGS AND POTENTIATES OPIOID RECEPTOR-MEDIATED ANALGESIA
10/02/2002EP1244915A2 Method for identifying inhibitors of cytokinesis
10/02/2002EP1244790A2 Nucleic acids encoding polypeptides having chips activity
10/02/2002EP1244789A2 Genes identified as required for proliferation of e. coli
10/02/2002EP1244786A1 Screening method for compounds capable of modularing egr-1-regulated expression
10/02/2002EP1244784A2 Methods and compositions for inhibiting neoplastic cell growth
10/02/2002EP1244780A2 Dna encoding the human serine protease t
10/02/2002EP1244708A1 Method for treating inflammation
10/02/2002EP1244700A2 Vesicle trafficking proteins
10/02/2002EP1244698A2 Novel human transporter proteins and polynucleotides encoding the same
10/02/2002EP1244695A2 Extracellular matrix and cell adhesion proteins as well as genes encoding them
10/02/2002EP1244686A1 Transforming growth factor alpha hiii
10/02/2002EP1244678A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
10/02/2002EP1244677A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
10/02/2002EP1244670A1 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
10/02/2002EP1244650A1 Arylamine derivatives and their use as anti-telomerase agent
10/02/2002EP1244640A1 Oxazolidinone derivatives
10/02/2002EP1244630A1 Amphiphilic polyamines, the use and method for synthesis thereof
1 ... 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 ... 1151